Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daclatasvir + asunaprevir
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Daclatasvir + asunaprevir is a fixed-dose combination of two direct-acting antiviral agents used for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotype 1b. Daclatasvir is an NS5A replication complex inhibitor that disrupts the function of the Hepatitis C virus nonstructural protein 5A (NS5A), which is essential for HCV RNA replication and virion assembly. Asunaprevir is an NS3 protease inhibitor that blocks viral polyprotein processing required for viral replication. This all-oral regimen was developed to provide an interferon-free and ribavirin-free option for HCV patients, including those with compensated cirrhosis. The combination has demonstrated high sustained virological response rates in clinical trials and was first globally approved in Japan[4][5][8].
- Brand names
- Daklinza + Sunvepra
- Other names
- DCV + ASV
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on daclatasvir + asunaprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daclatasvir + asunaprevir.